Astrazeneca

FromAstraZeneca ([email protected])
Subject (49)Tezspire nasal polyps trial met primary endpoints
Preheader (128)Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
Typography
Arial
Colors
Text Analysis
Body Words225
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px754 px
X-Spam Score-0.4
Preheader OptimizedNo
Timing
Day of WeekTuesday
TimeEarly Morning

Tezspire nasal polyps trial met primary endpoints

Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
Tezspire nasal polyps trial met primary endpoints